Chronic Otitis Media Tympanic Membrane PerforationNCT07664319
Effect of Platelet-Rich Plasma on Eardrum Healing and Hearing After Tympanoplasty in Adults
A study testing Autologous platelet-rich plasma (PRP)-impregnated Spongostan and Dry Spongostan (absorbable gelatin sponge) in people with Chronic Otitis Media Tympanic Membrane Perforation, run by Ebubekir Toprak at 1 site in Turkey (Türkiye).
Trial summary
This single-center controlled trial evaluated whether intraoperative application of autologous platelet-rich plasma (PRP)-impregnated absorbable gelatin sponge improves graft take rates and audiological outcomes in adults undergoing tympanoplasty for chronic otitis media with tympanic membrane perforation. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Otitis Media Tympanic Membrane Perforation
- What is being tested?
- Autologous platelet-rich plasma (PRP)-impregnated Spongostan and Dry Spongostan (absorbable gelatin sponge)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Apr 2023to 31 Aug 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Central tympanic membrane perforation present for at least 6 months No active discharge in the preceding 3 months Able to undergo and cooperate with preoperative pure-tone audiometry Available for follow-up
Who cannot join
- Planned concurrent mastoidectomy Cholesteatoma (on imaging or intraoperative inspection) History of ventilation tube insertion on the affected side Revision surgery Uncontrolled hypertension or diabetes mellitus Coagulation disorder or antiplatelet/anticoagulant therapy Anaemia (Hgb <12 g/dL) or thrombocytopenia (platelets <150,000/µL) Active malignancy Serious psychiatric illness Occupation involving high pressure changes (e.g., diver, pilot) Rheumatic disease history
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Sbü Sisli Hamidiye Etfal Eah
Istanbul, Sisli, 34700
About this study
Official title: Intraoperative Use of Platelet-Rich Plasma in Tympanoplasty: Effects on Graft Success and Audiological Outcomes - A Prospective Controlled Trial
This single-center controlled trial evaluated whether intraoperative application of autologous platelet-rich plasma (PRP)-impregnated absorbable gelatin sponge improves graft take rates and audiological outcomes in adults undergoing tympanoplasty for chronic otitis media with tympanic membrane perforation. Forty-eight patients were allocated by systematic alternation to a PRP group (PRP-impregnated Spongostan placed in the middle ear and lateral to the graft) or a control group (dry Spongostan). The primary outcome was graft integrity at two months; the secondary outcome was improvement in the air-bone gap.
Read the detailed description
Study design and ethics This prospective, single-center, randomized controlled trial was conducted at the Otolaryngology-Head and Neck Surgery Clinic of Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, between April 1 and June 30, 2023. The protocol received ethics committee approval (decision no. 3857, April 4, 2023). All participants provided written informed consent before enrolment. The trial was conducted in accordance with the Declaration of Helsinki.
Participants Adults aged 18-65 years were eligible if they had a central tympanic membrane perforation present for at least six months without active discharge in the preceding three months, were able to undergo and cooperate with preoperative pure-tone audiometry, and were available for follow-up. Exclusion criteria were: planned concurrent mastoidectomy, cholesteatoma on preoperative imaging or intraoperative inspection, a history of ventilation tube insertion on the affected side, revision surgery, uncontrolled hypertension or diabetes mellitus, coagulation disorder or antiplatelet/anticoagulant therapy, anaemia (Hgb <12 g/dL) or thrombocytopaenia (platelets <150,000/μL), active malignancy, and serious psychiatric illness.
Randomization Patients who met inclusion criteria were allocated by simple alternation: the first eligible patient was assigned to the PRP group, the second to the control group, the third to the PRP group, and so on. Patients were not informed of their group assignment (single-blind design). Surgeons were necessarily aware of group allocation.
Sample size Sample size was calculated with G*Power version 3.1.6. Based on an expected large effect size (Cohen's d = 0.62) derived from comparable prospective cohort data, a two-sided α of 0.05, and a power of 80%, the required sample was 48 patients (24 per group).
PRP preparation PRP was prepared manually at the start of each operation in the PRP group. After intravenous access was established, 8.5 mL of venous blood was drawn into a glass tube containing 1.5 mL of acid citrate dextrose (ACD-A solution; Becton Dickinson, Plymouth, UK) using an 18-gauge needle. The tube was centrifuged at 419 × g (2,500 rpm) for 8 minutes in a Tomos Centrifuge 802B (Tomos Life Science Group, Shanghai, China), balanced against a tube of equal weight containing normal saline. The platelet-rich buffy coat layer and the overlying plasma were carefully aspirated using a spinal cannula into a sterile, anticoagulant- free 10-mL tube. This tube was then centrifuged at 822 × g (3,500 rpm) for 8 minutes. The upper two-thirds of the supernatant were discarded, and the remaining platelet concentrate was gently resuspended by inverting the tube several times. This final product was used to saturate the spongostans immediately before placement.
Surgical technique The surgeries were performed under general anesthesia by one of six experienced ENT specialists. The approach (transcanal, endoauricular, or retroauricular) was determined preoperatively based on the location and size of the perforation, the anatomy of the external auditory canal, and the surgeon's preference. After standard preparation and local infiltration with 20 mg/mL lidocaine plus 0.0125 mg/mL epinephrine, the perforation edges were de- epithelialized with an instrument. The ossicular chain was examined and reconstructed as needed. In the PRP group, PRP-impregnated spongy bone was placed in the middle ear cavity and next to the graft. In the control group, dry spongy bone was placed in the same positions. The graft material (cartilage, temporal fascia, or fat) was selected according to the perforation characteristics and the surgeon's preference. An under- or over-under placement technique was used as needed. The external auditory canal was filled with antibiotic-impregnated gauze strips (bacitracin 500 IU/g + neomycin 5 mg/g ointment). All patients received 0.3% ciprofloxacin ear drops three times a day for one week after surgery.
Outcome measures and follow-up Patients were reviewed at two weeks (suture removal and packing removal) and at two months. At the two-month visit, the tympanic membrane was examined under microscopy and graft integrity was recorded (binary outcome: intact or perforated). Pure-tone audiometry was performed in a sound-treated booth using an Interacoustics AC 40 audiometer in accordance with ISO standards and American Speech-Language-Hearing Association criteria. Thresholds were measured at 250, 500, 1000, 2000, and 4000 Hz by air and bone conduction. The ABG was calculated as the mean air-bone gap across 500, 1000, 2000, and 4000 Hz. Hearing gain was defined as the difference between preoperative and postoperative ABG. Perforation area was measured intraoperatively using a calibrated 2-mm Rosen elevator and diamond burrs of known diameter; it was recorded for descriptive purposes only and was not a selection criterion.
Statistical analysis Analyses were performed with SPSS 15.0 for Windows. Categorical variables were compared with Chi-square tests; continuous variables were compared with independent- samples t-tests when normally distributed (Shapiro-Wilk test, p>0.05) or Mann-Whitney U tests otherwise. Within-group pre- to postoperative changes were assessed with paired t-tests or Wilcoxon signed-rank tests as appropriate. Bonferroni correction was applied for multiple comparisons. Statistical significance was defined as p<0.05 (two-tailed).
- Being tested
- Autologous platelet-rich plasma (PRP)-impregnated Spongostan, Dry Spongostan (absorbable gelatin sponge)
- Keywords
- Tympanoplasty; Platelet-Rich Plasma; Myringoplasty; Air-Bone Gap; Graft Success
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Autologous platelet-rich plasma (PRP)-impregnated SpongostanBiological
PRP-impregnated absorbable gelatin sponge placed in the middle ear and lateral to the graft during tympanoplasty
Dry Spongostan (absorbable gelatin sponge)Other
Dry absorbable gelatin sponge placed in the same positions without PRP
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 - PRP group | Experimental | Autologous PRP-impregnated Spongostan placed in the middle ear and lateral to the graft during tympanoplasty. Receives: Biological: Autologous platelet-rich plasma (PRP)-impregnated Spongostan |
| Arm 2 - Control group | Active comparator | Dry Spongostan placed in the same positions, without PRP. Receives: Other: Dry Spongostan (absorbable gelatin sponge) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Graft integrity (intact tympanic membrane)
Proportion of patients with an intact tympanic membrane (no residual perforation) on otomicroscopic examination.
Measured: 2 months postoperatively
Secondary outcomes (1)
Air-bone gap (ABG)
Mean air-bone gap on pure-tone audiometry, averaged across 500, 1000, 2000, and 4000 Hz.
Measured: 2 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2026
- Study start1 Apr 2023
- Primary completion30 Jun 2023
- Study completion31 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Otitis Media Tympanic Membrane PerforationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ebubekir Toprak
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Ebubekir Toprak, Sisli Hamidiye Etfal Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07664319
- Sponsor's protocol ID
- Ethics committee number: 3857
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 24 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraoperative Use of Platelet-Rich Plasma in Tympanoplasty: Effects on Graft Success and Audiological Outcomes - A Prospective Controlled Trial
- ClinicalTrials.gov ID
- NCT07664319
- Acronym / sponsor ID
- Ethics committee number: 3857
- Keywords
- Tympanoplasty; Platelet-Rich Plasma; Myringoplasty; Air-Bone Gap; Graft Success
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Ebubekir ToprakUniversity, hospital or other
- Study start
- 1 Apr 2023 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 31 Aug 2023 (actual)
- First posted
- 24 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single-center controlled trial evaluated whether intraoperative application of autologous platelet-rich plasma (PRP)-impregnated absorbable gelatin sponge improves graft take rates and audiological outcomes in adults undergoing tympanoplasty for chronic otitis media with tympanic membrane perforation. Forty-eight patients were allocated by systematic alternation to a PRP group (PRP-impregnated Spongostan placed in the middle ear and lateral to the graft) or a control group (dry Spongostan). The primary outcome was graft integrity at two months; the secondary outcome was improvement in the air-bone gap.
Detailed description
Study design and ethics This prospective, single-center, randomized controlled trial was conducted at the Otolaryngology-Head and Neck Surgery Clinic of Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, between April 1 and June 30, 2023. The protocol received ethics committee approval (decision no. 3857, April 4, 2023). All participants provided written informed consent before enrolment. The trial was conducted in accordance with the Declaration of Helsinki.
Participants Adults aged 18-65 years were eligible if they had a central tympanic membrane perforation present for at least six months without active discharge in the preceding three months, were able to undergo and cooperate with preoperative pure-tone audiometry, and were available for follow-up. Exclusion criteria were: planned concurrent mastoidectomy, cholesteatoma on preoperative imaging or intraoperative inspection, a history of ventilation tube insertion on the affected side, revision surgery, uncontrolled hypertension or diabetes mellitus, coagulation disorder or antiplatelet/anticoagulant therapy, anaemia (Hgb <12 g/dL) or thrombocytopaenia (platelets <150,000/μL), active malignancy, and serious psychiatric illness.
Randomization Patients who met inclusion criteria were allocated by simple alternation: the first eligible patient was assigned to the PRP group, the second to the control group, the third to the PRP group, and so on. Patients were not informed of their group assignment (single-blind design). Surgeons were necessarily aware of group allocation.
Sample size Sample size was calculated with G*Power version 3.1.6. Based on an expected large effect size (Cohen's d = 0.62) derived from comparable prospective cohort data, a two-sided α of 0.05, and a power of 80%, the required sample was 48 patients (24 per group).
PRP preparation PRP was prepared manually at the start of each operation in the PRP group. After intravenous access was established, 8.5 mL of venous blood was drawn into a glass tube containing 1.5 mL of acid citrate dextrose (ACD-A solution; Becton Dickinson, Plymouth, UK) using an 18-gauge needle. The tube was centrifuged at 419 × g (2,500 rpm) for 8 minutes in a Tomos Centrifuge 802B (Tomos Life Science Group, Shanghai, China), balanced against a tube of equal weight containing normal saline. The platelet-rich buffy coat layer and the overlying plasma were carefully aspirated using a spinal cannula into a sterile, anticoagulant- free 10-mL tube. This tube was then centrifuged at 822 × g (3,500 rpm) for 8 minutes. The upper two-thirds of the supernatant were discarded, and the remaining platelet concentrate was gently resuspended by inverting the tube several times. This final product was used to saturate the spongostans immediately before placement.
Surgical technique The surgeries were performed under general anesthesia by one of six experienced ENT specialists. The approach (transcanal, endoauricular, or retroauricular) was determined preoperatively based on the location and size of the perforation, the anatomy of the external auditory canal, and the surgeon's preference. After standard preparation and local infiltration with 20 mg/mL lidocaine plus 0.0125 mg/mL epinephrine, the perforation edges were de- epithelialized with an instrument. The ossicular chain was examined and reconstructed as needed. In the PRP group, PRP-impregnated spongy bone was placed in the middle ear cavity and next to the graft. In the control group, dry spongy bone was placed in the same positions. The graft material (cartilage, temporal fascia, or fat) was selected according to the perforation characteristics and the surgeon's preference. An under- or over-under placement technique was used as needed. The external auditory canal was filled with antibiotic-impregnated gauze strips (bacitracin 500 IU/g + neomycin 5 mg/g ointment). All patients received 0.3% ciprofloxacin ear drops three times a day for one week after surgery.
Outcome measures and follow-up Patients were reviewed at two weeks (suture removal and packing removal) and at two months. At the two-month visit, the tympanic membrane was examined under microscopy and graft integrity was recorded (binary outcome: intact or perforated). Pure-tone audiometry was performed in a sound-treated booth using an Interacoustics AC 40 audiometer in accordance with ISO standards and American Speech-Language-Hearing Association criteria. Thresholds were measured at 250, 500, 1000, 2000, and 4000 Hz by air and bone conduction. The ABG was calculated as the mean air-bone gap across 500, 1000, 2000, and 4000 Hz. Hearing gain was defined as the difference between preoperative and postoperative ABG. Perforation area was measured intraoperatively using a calibrated 2-mm Rosen elevator and diamond burrs of known diameter; it was recorded for descriptive purposes only and was not a selection criterion.
Statistical analysis Analyses were performed with SPSS 15.0 for Windows. Categorical variables were compared with Chi-square tests; continuous variables were compared with independent- samples t-tests when normally distributed (Shapiro-Wilk test, p>0.05) or Mann-Whitney U tests otherwise. Within-group pre- to postoperative changes were assessed with paired t-tests or Wilcoxon signed-rank tests as appropriate. Bonferroni correction was applied for multiple comparisons. Statistical significance was defined as p<0.05 (two-tailed).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm 1 - PRP group | Experimental | Biological: Autologous platelet-rich plasma (PRP)-impregnated SpongostanAutologous PRP-impregnated Spongostan placed in the middle ear and lateral to the graft during tympanoplasty. |
| Arm 2 - Control group | Active comparator | Other: Dry Spongostan (absorbable gelatin sponge)Dry Spongostan placed in the same positions, without PRP. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Central tympanic membrane perforation present for at least 6 months No active discharge in the preceding 3 months Able to undergo and cooperate with preoperative pure-tone audiometry Available for follow-up
Key exclusion criteria (1 listed)
- Planned concurrent mastoidectomy Cholesteatoma (on imaging or intraoperative inspection) History of ventilation tube insertion on the affected side Revision surgery Uncontrolled hypertension or diabetes mellitus Coagulation disorder or antiplatelet/anticoagulant therapy Anaemia (Hgb <12 g/dL) or thrombocytopenia (platelets <150,000/µL) Active malignancy Serious psychiatric illness Occupation involving high pressure changes (e.g., diver, pilot) Rheumatic disease history
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Autologous platelet-rich plasma (PRP)-impregnated SpongostanPRP-impregnated absorbable gelatin sponge placed in the middle ear and lateral to the graft during tympanoplasty | Biological | Arm 1 - PRP group |
| Dry Spongostan (absorbable gelatin sponge)Dry absorbable gelatin sponge placed in the same positions without PRP | Other | Arm 2 - Control group |
Primary outcome
Graft integrity (intact tympanic membrane)
Time frame: 2 months postoperatively
Proportion of patients with an intact tympanic membrane (no residual perforation) on otomicroscopic examination.
1 secondary outcome
Air-bone gap (ABG)
Time frame: 2 months postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Otitis Media Tympanic Membrane Perforation
Recruiting
Platelet-Rich Fibrin in Revision Cartilage Tympanoplasty
Tympanic Membrane Perforation, Chronic Otitis Media
Not yet recruiting
Outcomes of Cartilage Tympanoplasty in Children
Tympanic Membrane Perforation, Conductive Hearing Loss
Not yet recruiting
Does Adding a Fascial Layer to the Cartilage in Tympanoplasty for Large Tympanic Membrane Perforation Affect the Overall Results?
Tympanic Membrane Perforation, Otitis Media
Not yet recruiting
Boomerang-Shaped Cartilage Graft in Endoscopic Tympanoplasty
Tympanic Membrane Perforation, Chronic Otitis Media
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Autologous platelet-rich plasma (PRP)-impregnated Spongostan and Dry Spongostan (absorbable gelatin sponge) in people with Chronic Otitis Media Tympanic Membrane Perforation, run by Ebubekir Toprak at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Graft integrity (intact tympanic membrane) (time frame: 2 months postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.